SEC Comment Letter 0000000000-23-005311 to Milestone Pharmaceuticals Inc. (MIST) (CIK 0001408443) (MIST)
Milestone Pharmaceuticals Inc. (MIST) (CIK 0001408443)
Date: May 18, 2023 · CIK: 0001408443 · Accession: 0000000000-23-005311
AI Filing Summary & Sentiment
File numbers found in text: 333-271949
Letter
United States securities and exchange commission logo May 18, 2023 Joseph Oliveto Chief Executive Officer Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montréal, Québec CA H4M 2X6 Re:Milestone Pharmaceuticals Inc. Registration Statement on Form S-3 Filed May 15, 2023 File No. 333-271949 Dear Joseph Oliveto: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nicolas H.R. Dumont
Show Raw Text
United States securities and exchange commission logo
May 18, 2023
Joseph Oliveto
Chief Executive Officer
Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 420
Montréal, Québec CA H4M 2X6
Re:Milestone Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed May 15, 2023
File No. 333-271949
Dear Joseph Oliveto:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nicolas H.R. Dumont